| 1. Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ, Hartley JA.. (1995) Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide., 38 (9): [PMID:7739008] [10.1021/jm00009a010] |
| 2. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG.. (1984) Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent., 27 (2): [PMID:6694168] [10.1021/jm00368a016] |
| 3. Dumont-Hornebeck B, Strube YN, Vasilescu D, Jean-Claude BJ.. (2000) Design and synthesis of a novel water soluble benzotetrazepinone., 10 (20): [PMID:11055348] [10.1016/s0960-894x(00)00461-3] |
| 4. Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ.. (2003) Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase., 13 (19): [PMID:12951113] [10.1016/s0960-894x(03)00553-5] |
| 5. Griffin RJ, Arris CE, Bleasdale C, Boyle FT, Calvert AH, Curtin NJ, Dalby C, Kanugula S, Lembicz NK, Newell DR, Pegg AE, Golding BT.. (2000) Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine., 43 (22): [PMID:11063604] [10.1021/jm000961o] |
| 6. White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, Maegley K, Newell DR, Srinivasan S, Golding BT.. (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase., 43 (22): [PMID:11063605] [10.1021/jm000950v] |
| 7. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z.. (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure., 45 (23): [PMID:12408707] [10.1021/jm020259n] |
| 8. Arrowsmith J, Jennings SA, Clark AS, Stevens MF.. (2002) Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs., 45 (25): [PMID:12459014] [10.1021/jm020936d] |
| 9. Wanner MJ, Koch M, Koomen GJ.. (2004) Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O(6)-benzylguanine., 47 (27): [PMID:15615536] [10.1021/jm049556d] |
| 10. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM.. (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1., 51 (20): [PMID:18800822] [10.1021/jm8001263] |
| 11. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL.. (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer., 52 (2): [PMID:19143569] [10.1021/jm801171j] |
| 12. Tong Y, Bouska JJ, Ellis PA, Johnson EF, Leverson J, Liu X, Marcotte PA, Olson AM, Osterling DJ, Przytulinska M, Rodriguez LE, Shi Y, Soni N, Stavropoulos J, Thomas S, Donawho CK, Frost DJ, Luo Y, Giranda VL, Penning TD.. (2009) Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents., 52 (21): [PMID:19888760] [10.1021/jm900697r] |
| 13. Rhee HK, Lim SY, Jung MJ, Kwon Y, Kim MH, Choo HY.. (2009) Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors., 17 (21): [PMID:19800803] [10.1016/j.bmc.2009.09.014] |
| 14. Penning TD, Zhu GD, Gong J, Thomas S, Gandhi VB, Liu X, Shi Y, Klinghofer V, Johnson EF, Park CH, Fry EH, Donawho CK, Frost DJ, Buchanan FG, Bukofzer GT, Rodriguez LE, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL.. (2010) Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor., 53 (8): [PMID:20337371] [10.1021/jm901775y] |
| 15. Toropov AA, Toropova AP, Raska I, Benfenati E.. (2010) QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations., 45 (4): [PMID:20106561] [10.1016/j.ejmech.2009.12.043] |
| 16. PubChem BioAssay data set, |
| 17. PubChem BioAssay data set, |
| 18. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 19. Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.. (2007) Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential., 47 (1): [PMID:17428028] [10.1021/ci6004542] |
| 20. Lowe R, Glen RC, Mitchell JB.. (2010) Predicting phospholipidosis using machine learning., 7 (5): [PMID:20799726] [10.1021/mp100103e] |
| 21. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 22. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 23. Unpublished dataset, |
| 24. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 25. PubChem BioAssay data set, |
| 26. PubChem BioAssay data set, |
| 27. Clarion L, Jacquard C, Sainte-Catherine O, Loiseau S, Filippini D, Hirlemann MH, Volle JN, Virieux D, Lecouvey M, Pirat JL, Bakalara N.. (2012) Oxaphosphinanes: new therapeutic perspectives for glioblastoma., 55 (5): [PMID:22268526] [10.1021/jm201428a] |
| 28. Goffin E, Lamoral-Theys D, Tajeddine N, de Tullio P, Mondin L, Lefranc F, Gailly P, Rogister B, Kiss R, Pirotte B.. (2012) N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis., 54 [PMID:22809560] [10.1016/j.ejmech.2012.06.050] |
| 29. Patil SA, Wang J, Li XS, Chen J, Jones TS, Hosni-Ahmed A, Patil R, Seibel WL, Li W, Miller DD.. (2012) New substituted 4H-chromenes as anticancer agents., 22 (13): [PMID:22608389] [10.1016/j.bmcl.2012.04.074] |
| 30. Zhu GD, Gong J, Gandhi VB, Liu X, Shi Y, Johnson EF, Donawho CK, Ellis PA, Bouska JJ, Osterling DJ, Olson AM, Park C, Luo Y, Shoemaker A, Giranda VL, Penning TD.. (2012) Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer., 20 (15): [PMID:22766219] [10.1016/j.bmc.2012.06.021] |
| 31. Vianna DR, Hamerski L, Figueiró F, Bernardi A, Visentin LC, Pires EN, Teixeira HF, Salbego CG, Eifler-Lima VL, Battastini AM, von Poser GL, Pinto AC.. (2012) Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species., 57 [PMID:23069682] [10.1016/j.ejmech.2012.09.007] |
| 32. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 33. Garelnabi EA, Pletsas D, Li L, Kiakos K, Karodia N, Hartley JA, Phillips RM, Wheelhouse RT.. (2012) Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR., 3 (12): [PMID:24900418] [10.1021/ml300132t] |
| 34. Patil R, Patil S, Wang X, Ma F, Orr WE, Li W, Yates CR, Geisert EE, Miller DD. (2011) Synthesis and evaluation of new 1,2,3,4-tetrahydroisoquinoline analogs as antiglioma agents, 20 (1): [10.1007/s00044-010-9356-8] |
| 35. Barthelemy-Requin M, Nugier J, Madonna S, Kraus J. (2012) Bloodbrain barrier permeability and transport studies of JLK1486: a new antiglioblastoma drug, 21 (7): [10.1007/s00044-011-9649-6] |
| 36. Pletsas D, Garelnabi EA, Li L, Phillips RM, Wheelhouse RT.. (2013) Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53., 56 (17): [PMID:23895620] [10.1021/jm401121k] |
| 37. Monteiro AS, Almeida J, Cabral G, Severino P, Videira PA, Sousa A, Nunes R, Pereira JD, Francisco AP, Perry MJ, Mendes E, Mendes E.. (2013) Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines., 70 [PMID:24125877] [10.1016/j.ejmech.2013.09.040] |
| 38. Giannini G, Battistuzzi G, Vesci L, Milazzo FM, De Paolis F, Barbarino M, Guglielmi MB, Carollo V, Gallo G, Artali R, Dallavalle S.. (2014) Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold., 24 (2): [PMID:24388690] [10.1016/j.bmcl.2013.12.048] |
| 39. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 40. PubChem BioAssay data set, |
| 41. PubChem BioAssay data set, |
| 42. Cebrian-Torrejon G, Kahn SA, Ferreira ME, Thirant C, Rojas de Arias A, Figadere B, Fournet A, Chneiweiss H, Poupon E. (2012) Alkaloids from Rutaceae: activities of canthin-6-one alkaloids and synthetic analogues on glioblastoma stems cells, 3 (7): [10.1039/C2MD20047C] |
| 43. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 44. Lauria A, Alfio A, Bonsignore R, Gentile C, Martorana A, Gennaro G, Barone G, Terenzi A, Almerico AM.. (2014) New benzothieno[3,2-d]-1,2,3-triazines with antiproliferative activity: synthesis, spectroscopic studies, and biological activity., 24 (15): [PMID:24986661] [10.1016/j.bmcl.2014.06.007] |
| 45. Ye X, Yu S, Liang Y, Huang H, Lian XY, Zhang Z.. (2014) Bioactive triterpenoid saponins and phenolic compounds against glioma cells., 24 (22): [PMID:25442304] [10.1016/j.bmcl.2014.09.087] |
| 46. Liu Z, Yao Y, Kogiso M, Zheng B, Deng L, Qiu JJ, Dong S, Lv H, Gallo JM, Li XN, Song Y.. (2014) Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity., 57 (20): [PMID:25271760] [10.1021/jm500660f] |
| 47. Maggio B, Raimondi MV, Raffa D, Plescia F, Cascioferro S, Cancemi G, Tolomeo M, Grimaudo S, Daidone G.. (2015) Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one., 96 [PMID:25874335] [10.1016/j.ejmech.2015.04.004] |
| 48. Aksenov AV, Smirnov AN, Magedov IV, Reisenauer MR, Aksenov NA, Aksenova IV, Pendleton AL, Nguyen G, Johnston RK, Rubin M, De Carvalho A, Kiss R, Mathieu V, Lefranc F, Correa J, Cavazos DA, Brenner AJ, Bryan BA, Rogelj S, Kornienko A, Frolova LV.. (2015) Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells., 58 (5): [PMID:25671501] [10.1021/jm501518y] |
| 49. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy., 58 (17): [PMID:26222319] [10.1021/acs.jmedchem.5b00680] |
| 50. Fu S, Xie Y, Tuo J, Wang Y, Zhu W, Wu S, Yan G, Hu H. (2015) Discovery of mitochondria-targeting berberine derivatives as the inhibitors of proliferation, invasion and migration against rat C6 and human U87 glioma cells, 6 (1): [10.1039/C4MD00264D] |
| 51. Quartararo CE, Reznik E, deCarvalho AC, Mikkelsen T, Stockwell BR.. (2015) High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma., 6 (8): [PMID:26288699] [10.1021/acsmedchemlett.5b00128] |
| 52. Elkamhawy A, Viswanath AN, Pae AN, Kim HY, Heo JC, Park WK, Lee CO, Yang H, Kim KH, Nam DH, Seol HJ, Cho H, Roh EJ.. (2015) Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM)., 103 [PMID:26355532] [10.1016/j.ejmech.2015.08.001] |
| 53. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.. (2015) Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme., 105 [PMID:26498573] [10.1016/j.ejmech.2015.10.020] |
| 54. Zhang J, Liu L, Wang B, Zhang Y, Wang L, Liu X, Che Y.. (2015) Phomanolides A and B from the Fungus Phoma sp.: Meroterpenoids Derived from a Putative Tropolonic Sesquiterpene via Hetero-Diels-Alder Reactions., 78 (12): [PMID:26651221] [10.1021/acs.jnatprod.5b00969] |
| 55. Gurrapu S, Jonnalagadda SK, Alam MA, Ronayne CT, Nelson GL, Solano LN, Lueth EA, Drewes LR, Mereddy VR.. (2016) Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents., 26 (14): [PMID:27241692] [10.1016/j.bmcl.2016.05.054] |
| 56. Daniele S, La Pietra V, Barresi E, Di Maro S, Da Pozzo E, Robello M, La Motta C, Cosconati S, Taliani S, Marinelli L, Novellino E, Martini C, Da Settimo F.. (2016) Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas., 59 (10): [PMID:27050782] [10.1021/acs.jmedchem.5b01767] |
| 57. WHO Anatomical Therapeutic Chemical Classification, |
| 58. British National Formulary (72nd edition), |
| 59. Rai R, Banerjee M, Wong DH, McCullagh E, Gupta A, Tripathi S, Riquelme E, Jangir R, Yadav S, Raja M, Melkani P, Dixit V, Patil U, Shrivastava R, Middya S, Olivares F, Guerrero J, Surya A, Pham SM, Bernales S, Protter AA, Hung DT, Chakravarty S.. (2016) Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide., 26 (20): [PMID:27614414] [10.1016/j.bmcl.2016.08.064] |
| 60. Henry S, Kidner R, Reisenauer MR, Magedov IV, Kiss R, Mathieu V, Lefranc F, Dasari R, Evidente A, Yu X, Ma X, Pertsemlidis A, Cencic R, Pelletier J, Cavazos DA, Brenner AJ, Aksenov AV, Rogelj S, Kornienko A, Frolova LV.. (2016) 5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells., 120 [PMID:27218860] [10.1016/j.ejmech.2016.05.004] |
| 61. da Silva DS, da Silva CEH, Soares MSP, Azambuja JH, de Carvalho TR, Zimmer GC, Frizzo CP, Braganhol E, Spanevello RM, Cunico W.. (2016) Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity., 124 [PMID:27614406] [10.1016/j.ejmech.2016.08.057] |
| 62. van Kuijk SJA, Parvathaneni NK, Niemans R, van Gisbergen MW, Carta F, Vullo D, Pastorekova S, Yaromina A, Supuran CT, Dubois LJ, Winum JY, Lambin P.. (2017) New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs., 127 [PMID:27823879] [10.1016/j.ejmech.2016.10.037] |
| 63. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 64. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 65. Zhou J, Ji M, Zhu Z, Cao R, Chen X, Xu B.. (2017) Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity., 132 [PMID:28340412] [10.1016/j.ejmech.2017.03.013] |
| 66. Sousa A, Sousa A, Santos F, Gaspar MM, Calado S, Pereira JD, Mendes E, Francisco AP, Perry MJ.. (2017) The selective cytotoxicity of new triazene compounds to human melanoma cells., 25 (15): [PMID:28602669] [10.1016/j.bmc.2017.04.049] |
| 67. Li S, Li G, Yang X, Meng Q, Yuan S, He Y, Sun D.. (2018) Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents., 28 (13): [PMID:29789258] [10.1016/j.bmcl.2018.05.035] |
| 68. Fu RG, Sun Y, Sheng WB, Liao DF.. (2017) Designing multi-targeted agents: An emerging anticancer drug discovery paradigm., 136 [PMID:28494256] [10.1016/j.ejmech.2017.05.016] |
| 69. (2016) 7 (12): [10.1039/C6MD00384B] |
| 70. Cousin D, Hummersone MG, Bradshaw TD, Zhang J, Moody CJ, Foreiter MB, Summers HS, Lewis W, Wheelhouse RT, Stevens MFG.. (2018) Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position., 9 (3): [PMID:30108945] [10.1039/C7MD00554G] |
| 71. Unpublished dataset, |
| 72. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 73. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 74. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 75. Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C, Poulsen SA.. (2019) Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma., 62 (8): [PMID:30925064] [10.1021/acs.jmedchem.9b00282] |
| 76. Yamasaki T, Buric D, Chacon C, Audran G, Braguer D, Marque SRA, Carré M, Brémond P.. (2019) Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells., 27 (10): [PMID:30975504] [10.1016/j.bmc.2019.03.029] |
| 77. Xu Z, Zhao SJ, Liu Y.. (2019) 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships., 183 [PMID:31546197] [10.1016/j.ejmech.2019.111700] |
| 78. Li B, Kuang Y, He JB, Tang R, Xu LL, Leung CH, Ma DL, Qiao X, Ye M.. (2020) Antcamphorols A-K, Cytotoxic and ROS Scavenging Triterpenoids from Antrodia camphorata., 83 (1): [PMID:31891260] [10.1021/acs.jnatprod.9b00580] |
| 79. Choi PJ, Cooper E, Schweder P, Mee E, Faull R, Denny WA, Dragunow M, Park TI, Jose J.. (2019) The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines., 29 (18): [PMID:31378572] [10.1016/j.bmcl.2019.07.051] |
| 80. Ding Y, Xue Q, Liu S, Hu K, Wang D, Wang T, Li Y, Guo H, Hao X, Ge W, Zhang Y, Li A, Li J, Chen Y, Zhang Q.. (2020) Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo., 63 (4): [PMID:31977207] [10.1021/acs.jmedchem.9b01328] |
| 81. Braga C, Vaz AR, Oliveira MC, Matilde Marques M, Moreira R, Brites D, Perry MJ.. (2019) Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability., 172 [PMID:30939350] [10.1016/j.ejmech.2019.03.048] |
| 82. Baker C, Rodrigues T, de Almeida BP, Barbosa-Morais NL, Bernardes GJL.. (2019) Natural product-drug conjugates for modulation of TRPV1-expressing tumors., 27 (12): [PMID:30885569] [10.1016/j.bmc.2019.03.025] |
| 83. (2017) Compositions and methods for treating cancer, |
| 84. de Moura Sperotto ND, Deves Roth C, Rodrigues-Junior VS, Ev Neves C, Reisdorfer Paula F, da Silva Dadda A, Bergo P, Freitas de Freitas T, Souza Macchi F, Moura S, Duarte de Souza AP, Campos MM, Valim Bizarro C, Santos DS, Basso LA, Machado P.. (2019) Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer., 62 (3): [PMID:30615449] [10.1021/acs.jmedchem.8b01305] |
| 85. Papeo G, Orsini P, Avanzi NR, Borghi D, Casale E, Ciomei M, Cirla A, Desperati V, Donati D, Felder ER, Galvani A, Guanci M, Isacchi A, Posteri H, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Montagnoli A.. (2019) Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515., 10 (4): [PMID:30996792] [10.1021/acsmedchemlett.8b00569] |
| 86. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 87. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 88. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection, [10.6019/CHEMBL4513141] |
| 89. Torres JP, Lin Z, Fenton DS, Leavitt LU, Niu C, Lam PY, Robes JM, Peterson RT, Concepcion GP, Haygood MG, Olivera BM, Schmidt EW.. (2020) Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide., 83 (4): [PMID:32186874] [10.1021/acs.jnatprod.0c00038] |
| 90. Maccallini C, Arias F, Gallorini M, Amoia P, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Cataldi A, Camacho ME, Amoroso R.. (2020) Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation., 11 (7): [PMID:32676156] [10.1021/acsmedchemlett.0c00285] |
| 91. Choi PJ, Cooper E, Schweder P, Mee E, Turner C, Faull R, Denny WA, Dragunow M, Park TI, Jose J.. (2020) PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines., 30 (14): [PMID:32527552] [10.1016/j.bmcl.2020.127252] |
| 92. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 93. Wang H,Ren B,Liu Y,Jiang B,Guo Y,Wei M,Luo L,Kuang X,Qiu M,Lv L,Xu H,Qi R,Yan H,Xu D,Wang Z,Huo CX,Zhu Y,Zhao Y,Wu Y,Qin Z,Su D,Tang T,Wang F,Sun X,Feng Y,Peng H,Wang X,Gao Y,Liu Y,Gong W,Yu F,Liu X,Wang L,Zhou C. (2020) Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development., 63 (24): [PMID:33264017] [10.1021/acs.jmedchem.0c01346] |
| 94. Xiang W,Quadery TM,Hamel E,Luckett-Chastain LR,Ihnat MA,Mooberry SL,Gangjee A. (2021) The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity., 29 [PMID:33310545] [10.1016/j.bmc.2020.115887] |
| 95. Cao C,Yang J,Chen Y,Zhou P,Wang Y,Du W,Zhao L,Chen Y. (2020) Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers., 63 (19): [PMID:32924477] [10.1021/acs.jmedchem.0c00821] |
| 96. Chang KF,Huang XF,Chang JT,Huang YC,Lo WS,Hsiao CY,Tsai NM. (2020) Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression., 83 (10): [PMID:32960603] [10.1021/acs.jnatprod.0c00580] |
| 97. Dai Z,Liu H,Wang B,Yang D,Zhu YY,Yan H,Zhu PF,Liu YP,Chen HC,Zhao YL,Zhao LX,Zhao XD,Liu HY,Luo XD. (2021) Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A., 210 [PMID:33310292] [10.1016/j.ejmech.2020.113068] |
| 98. Neves BJ,Agnes JP,Gomes MDN,Henriques Donza MR,Gonçalves RM,Delgobo M,Ribeiro de Souza Neto L,Senger MR,Silva-Junior FP,Ferreira SB,Zanotto-Filho A,Andrade CH. (2020) Efficient identification of novel anti-glioma lead compounds by machine learning models., 189 [PMID:31978780] [10.1016/j.ejmech.2019.111981] |
| 99. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 100. Li B, Kuang Y, Yi Y, Qiao X, Liang L, Ye M.. (2021) Chemical modifications of ergostane-type triterpenoids from Antrodia camphorata and their cytotoxic activities., 43 [PMID:33915258] [10.1016/j.bmcl.2021.128066] |
| 101. Fan X, Li J, Long L, Shi T, Liu D, Tan W, Zhang H, Wu X, Lei X, Wang Z.. (2021) Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma., 222 [PMID:34091208] [10.1016/j.ejmech.2021.113564] |
| 102. Granada M, Mendes E, Perry MJ, Penetra MJ, Gaspar MM, Pinho JO, Serra S, António CT, Francisco AP.. (2021) Sulfur Analogues of Tyrosine in the Development of Triazene Hybrid Compounds: A New Strategy against Melanoma., 12 (11.0): [PMID:34795855] [10.1021/acsmedchemlett.1c00252] |
| 103. Walunj D, Thankarajan E, Prasad C, Tuchinsky H, Baldan S, Sherman MY, Patsenker L, Gellerman G.. (2021) Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene., 225 [PMID:34507011] [10.1016/j.ejmech.2021.113811] |
| 104. Gao RD, Hin N, Prchalová E, Pal A, Lam J, Rais R, Slusher BS, Tsukamoto T.. (2021) Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor., 50 [PMID:34400301] [10.1016/j.bmcl.2021.128321] |
| 105. He Z, Charleton C, Devine RW, Kelada M, Walsh JMD, Conway GE, Gunes S, Mondala JRM, Tian F, Tiwari B, Kinsella GK, Malone R, O'Shea D, Devereux M, Wang W, Cullen PJ, Stephens JC, Curtin JF.. (2021) Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma., 224 [PMID:34384944] [10.1016/j.ejmech.2021.113736] |
| 106. Nguyen P, Doan P, Rimpilainen T, Konda Mani S, Murugesan A, Yli-Harja O, Candeias NR, Kandhavelu M.. (2021) Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment., 64 (15.0): [PMID:34304559] [10.1021/acs.jmedchem.1c00277] |
| 107. Yuan P, Gu X, Ni X, Qi Y, Shao X, Xu X, Liu J, Qian X.. (2021) Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides., 51 [PMID:34534673] [10.1016/j.bmcl.2021.128371] |
| 108. Li J, Hu X, Luo T, Lu Y, Feng Y, Zhang H, Liu D, Fan X, Wang Y, Jiang L, Wang Y, Hao X, Shi T, Wang Z.. (2021) N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation., 226 [PMID:34537445] [10.1016/j.ejmech.2021.113817] |
| 109. Gerlach SL, Dunlop RA, Metcalf JS, Banack SA, Cox PA.. (2022) Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide., 85 (1.0): [PMID:35044783] [10.1021/acs.jnatprod.1c00595] |
| 110. Zhou J, Ji M, Wang X, Zhao H, Cao R, Jin J, Li Y, Chen X, Sheng L, Chen X, Xu B.. (2021) Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis., 64 (22.0): [PMID:34748333] [10.1021/acs.jmedchem.1c01522] |
| 111. Pavletić P, Semeano A, Yano H, Bonifazi A, Giorgioni G, Piergentili A, Quaglia W, Sabbieti MG, Agas D, Santoni G, Pallini R, Ricci-Vitiani L, Sabato E, Vistoli G, Del Bello F.. (2022) Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma., 65 (18.0): [PMID:36098685] [10.1021/acs.jmedchem.2c00840] |
| 112. Lu Y, Feng Y, Li Z, Li J, Zhang H, Hu X, Jiang W, Shi T, Wang Z.. (2022) Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression., 227 [PMID:34656900] [10.1016/j.ejmech.2021.113908] |
| 113. Franco Pinto J, Fillion A, Duchambon P, Bombard S, Granzhan A.. (2022) Acridine-O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity., 227 [PMID:34731767] [10.1016/j.ejmech.2021.113909] |
| 114. He Y, Yang C, Wang Y, Sacher JR, Sims MM, Pfeffer LM, Miller DD.. (2022) Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells., 53 [PMID:34863065] [10.1016/j.bmc.2021.116533] |
| 115. Zhang MM, Jia Y, Li P, Qiao Y, Han KL.. (2021) New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme., 64 (12.0): [PMID:34096701] [10.1021/acs.jmedchem.1c00559] |
| 116. Phull MS, Jadav SS, Gundla R, Mainkar PS.. (2021) A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors., 212 [PMID:33445154] [10.1016/j.ejmech.2020.113149] |
| 117. Hassan AHE, Lee KT, Lee YS.. (2020) Flavone-based arylamides as potential anticancers: Design, synthesis and in vitro cell-based/cell-free evaluations., 187 [PMID:31877541] [10.1016/j.ejmech.2019.111965] |
| 118. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
| 119. European Medicines Agency, |
